1272 studies found for:    Ovarian Cancer: Clinical Trials
Show Display Options
Rank Status Study
21 Not yet recruiting Trial on Radical Upfront Surgery in Advanced Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Procedure: PDS;   Drug: 6 cycles of standard chemotherapy;   Drug: 3 cycles of standard NACT;   Procedure: IDS;   Drug: 3 cycles of standard chemotherapy
22 Recruiting ICON8: Weekly Chemotherapy in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Paclitaxel
23 Completed Assess Cancer in Ovarian Tumors With Biomarkers.
Condition: Ovarian Tumor
Intervention: Procedure: Blood Draw
24 Completed A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: ABT-888;   Drug: pegylated liposomal doxorubicin;   Drug: temozolomide
25 Completed Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
Conditions: Platinum Refractory Epithelial Ovarian Cancer;   Primary Cancer of the Peritoneum;   Cancer of the Fallopian Tube
Interventions: Drug: Sunitinib;   Drug: SUNITINIB
26 Active, not recruiting Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Pimasertib once daily;   Drug: Pimasertib placebo;   Drug: SAR245409 placebo;   Drug: SAR245409;   Drug: Pimasertib twice daily
27 Active, not recruiting Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
Condition: Ovarian Cancer
Intervention: Drug: IMAB027
28 Recruiting A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Condition: Ovarian Cancer
Interventions: Drug: Niraparib;   Drug: Placebo
29 Recruiting CT Antigen TCR-redirected T Cells for Ovarian Cancer.
Condition: Ovarian Cancer
Intervention: Biological: NYESO-1c259 T cells
30 Terminated Clinical Trial for Ovarian Cancer (OvaRex®)
Condition: Ovarian Cancer
Intervention: Drug: oregovomab
31 Withdrawn CA-125 in Screening Patients at High Risk for Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Other: physiologic testing;   Procedure: study of high risk factors
32 Recruiting The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial
Condition: Ovarian Cancer (Epithelial)
Intervention: Radiation: involved-field radiation therapy
33 Completed Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
Conditions: Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Leukemia;   Liver Cancer;   Lymphoma;   Neuroblastoma;   Ovarian Cancer;   Psychosocial Effects of Cancer and Its Treatment;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: psychosocial assessment and care
34 Recruiting Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasms
Interventions: Biological: Vigil;   Biological: Placebo
35 Completed
Has Results
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Topotecan;   Drug: Pegylated liposomal doxorubicin (PLD);   Drug: BI 6727
36 Terminated
Has Results
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients
Condition: Ovarian Cancer
Interventions: Biological: Abagovomab;   Biological: Placebo
37 Active, not recruiting A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women
Condition: Epithelial Ovarian Cancer
Interventions: Procedure: CA125 assay on Abbott Architect i1000SR platform;   Procedure: HE4 assay on Architect i1000SR platform;   Procedure: Transvaginal Ultrasound
38 Completed
Has Results
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Extraovarian Peritoneal Cancer;   Fallopian Tube Carcinoma
Intervention: Drug: Ontak
39 Active, not recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg
40 Terminated
Has Results
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Extraovarian Peritoneal Cancer;   Fallopian Tube Carcinoma
Intervention: Drug: Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years